RARE Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-04-24 | 2022 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 796,154 | 0 | 7,463,295 | 558,000 | 12,200 | 12,140,330 |
| 2023-04-24 | 2020 | Mardi Dier Former Chief Financial Officer and Executive Vice President | 116,346 | 100,000 | 3,820,000 | 0 | 0 | 6,120,642 |
| 2023-04-24 | 2021 | Mardi Dier Former Chief Financial Officer and Executive Vice President | 561,539 | 0 | 1,653,212 | 247,523 | 3,173 | 3,331,874 |
| 2023-04-24 | 2022 | Mardi Dier Former Chief Financial Officer and Executive Vice President | 607,346 | 0 | 2,928,368 | 0 | 8,492 | 4,436,756 |
| 2023-04-24 | 2020 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 480,063 | 0 | 723,432 | 267,138 | 0 | 2,177,640 |
| 2023-04-24 | 2021 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 509,939 | 0 | 1,653,212 | 224,942 | 8,700 | 3,263,220 |
| 2023-04-24 | 2022 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 533,315 | 0 | 2,007,768 | 260,678 | 12,200 | 3,706,511 |
| 2023-04-24 | 2020 | Erik Harris Chief Commercial Officer and Executive Vice President | 501,247 | 0 | 723,432 | 292,613 | 0 | 2,224,299 |
| 2023-04-24 | 2021 | Erik Harris Chief Commercial Officer and Executive Vice President | 543,846 | 0 | 1,653,212 | 245,025 | 8,700 | 3,317,210 |
| 2023-04-24 | 2022 | Erik Harris Chief Commercial Officer and Executive Vice President | 566,331 | 0 | 2,007,768 | 269,706 | 12,200 | 3,748,555 |
| 2023-04-24 | 2020 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 546,686 | 0 | 695,392 | 297,731 | 0 | 2,214,680 |
| 2023-04-24 | 2021 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 567,123 | 0 | 1,653,212 | 249,260 | 8,700 | 3,344,722 |
| 2023-04-24 | 2022 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 596,000 | 0 | 2,007,768 | 246,750 | 12,200 | 3,755,268 |
| 2023-04-24 | 2020 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 759,231 | 0 | 1,906,720 | 668,850 | 6,550 | 5,144,220 |
| 2023-04-24 | 2021 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 768,846 | 0 | 5,410,512 | 499,100 | 8,700 | 9,522,738 |
| 2022-04-28 | 2021 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 768,846 | 0 | 5,410,512 | 499,100 | 8,700 | 9,522,738 |
| 2022-04-28 | 2019 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 714,000 | 0 | 2,702,000 | 479,808 | 6,550 | 6,553,142 |
| 2022-04-28 | 2021 | Mardi Dier Chief Financial Officer and Executive Vice President | 561,539 | 0 | 1,653,212 | 247,523 | 3,173 | 3,331,874 |
| 2022-04-28 | 2020 | Mardi Dier Chief Financial Officer and Executive Vice President | 116,346 | 100,000 | 3,820,000 | 0 | 0 | 6,120,642 |
| 2022-04-28 | 2021 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 567,123 | 0 | 1,653,212 | 249,260 | 8,700 | 3,344,722 |
| 2022-04-28 | 2020 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 546,686 | 0 | 695,392 | 297,731 | 0 | 2,214,680 |
| 2022-04-28 | 2019 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 511,186 | 0 | 878,150 | 230,076 | 2,729 | 2,485,654 |
| 2022-04-28 | 2021 | Erik Harris Chief Commercial Officer and Executive Vice President | 543,846 | 0 | 1,653,212 | 245,025 | 8,700 | 3,317,210 |
| 2022-04-28 | 2020 | Erik Harris Chief Commercial Officer and Executive Vice President | 501,247 | 0 | 723,432 | 292,613 | 0 | 2,224,299 |
| 2022-04-28 | 2019 | Erik Harris Chief Commercial Officer and Executive Vice President | 418,077 | 0 | 691,705 | 201,488 | 0 | 2,273,392 |
| 2022-04-28 | 2021 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 509,939 | 0 | 1,653,212 | 224,942 | 8,700 | 3,263,220 |
| 2022-04-28 | 2020 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 480,063 | 0 | 723,432 | 267,138 | 0 | 2,177,641 |
| 2022-04-28 | 2019 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 447,690 | 0 | 1,756,300 | 205,490 | 0 | 3,333,238 |
| 2022-04-28 | 2020 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 759,231 | 0 | 1,906,720 | 668,850 | 6,550 | 5,144,220 |
| 2021-04-29 | 2020 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 759,231 | 0 | 1,906,720 | 668,850 | 6,550 | 5,144,220 |
| 2021-04-29 | 2019 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 714,000 | 0 | 2,702,000 | 479,808 | 6,550 | 6,553,142 |
| 2021-04-29 | 2018 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 679,952 | 0 | 944,385 | 428,400 | 6,550 | 4,812,800 |
| 2021-04-29 | 2020 | Mardi Dier Chief Financial Officer and Executive Vice President | 116,346 | 100,000 | 3,820,000 | 0 | 0 | 6,120,642 |
| 2021-04-29 | 2020 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 546,686 | 0 | 695,392 | 297,731 | 0 | 2,214,680 |
| 2021-04-29 | 2019 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 511,186 | 0 | 878,150 | 230,076 | 2,729 | 2,485,654 |
| 2021-04-29 | 2018 | Camille L. Bedrosian, M.D. Chief Medical Officer and Executive Vice President | 442,308 | 210,000 | 990,000 | 189,274 | 97,563 | 4,836,128 |
| 2021-04-29 | 2020 | Erik Harris Chief Commercial Officer and Executive Vice President | 501,247 | 0 | 723,432 | 292,613 | 0 | 2,224,299 |
| 2021-04-29 | 2019 | Erik Harris Chief Commercial Officer and Executive Vice President | 418,077 | 0 | 691,705 | 201,488 | 0 | 2,273,392 |
| 2021-04-29 | 2018 | Erik Harris Chief Commercial Officer and Executive Vice President | 356,154 | 7,500 | 31,480 | 132,300 | 0 | 641,070 |
| 2021-04-29 | 2020 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 480,063 | 0 | 723,432 | 267,138 | 0 | 2,177,641 |
| 2021-04-29 | 2019 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 447,690 | 0 | 1,756,300 | 205,490 | 0 | 3,333,238 |
| 2021-04-29 | 2018 | John R. Pinion II Chief Quality Officer and Executive Vice President, Translational Sciences | 430,320 | 0 | 217,935 | 188,030 | 0 | 1,564,878 |
| 2021-04-29 | 2020 | Shalini Sharp Former Chief Financial Officer and Executive Vice President | 499,638 | 0 | 0 | 293,612 | 0 | 793,249 |
| 2021-04-29 | 2019 | Shalini Sharp Former Chief Financial Officer and Executive Vice President | 484,548 | 0 | 945,700 | 218,178 | 0 | 2,572,184 |
| 2021-04-29 | 2018 | Shalini Sharp Former Chief Financial Officer and Executive Vice President | 470,435 | 0 | 339,010 | 198,695 | 0 | 2,027,960 |
| 2020-04-29 | 2019 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 714,000 | 0 | 2,702,000 | 479,808 | 39,887 | 6,586,479 |
| 2020-04-29 | 2017 | Thomas Kassberg Chief Business Officer and Executive Vice President | 418,443 | 0 | 335,243 | 168,600 | 32,697 | 2,331,661 |
| 2020-04-29 | 2018 | Thomas Kassberg Chief Business Officer and Executive Vice President | 441,340 | 0 | 242,150 | 189,600 | 32,852 | 1,692,660 |
| 2020-04-29 | 2019 | Thomas Kassberg Chief Business Officer and Executive Vice President | 474,000 | 0 | 878,150 | 206,901 | 33,937 | 2,456,501 |
| 2020-04-29 | 2018 | Camille L. Bedrosian, M.D. Chief Medical Officer | 442,308 | 210,000 | 990,000 | 189,274 | 107,727 | 4,846,292 |
| 2020-04-29 | 2019 | Camille L. Bedrosian, M.D. Chief Medical Officer | 511,186 | 0 | 878,150 | 230,076 | 13,891 | 2,496,816 |
| 2020-04-29 | 2017 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 412,568 | 0 | 308,603 | 170,459 | 36,491 | 1,919,329 |
| 2020-04-29 | 2018 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 430,320 | 0 | 217,935 | 188,030 | 36,346 | 1,601,074 |
| 2020-04-29 | 2019 | John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences | 447,690 | 0 | 1,756,300 | 205,490 | 37,472 | 3,370,530 |
| 2020-04-29 | 2017 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 455,785 | 0 | 424,043 | 188,315 | 32,697 | 2,642,719 |
| 2020-04-29 | 2018 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 470,435 | 0 | 339,010 | 198,695 | 32,827 | 2,060,787 |
| 2020-04-29 | 2019 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 484,548 | 0 | 945,700 | 218,178 | 33,337 | 2,605,521 |
| 2020-04-29 | 2017 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 638,115 | 0 | 1,319,303 | 393,000 | 39,247 | 6,684,899 |
| 2020-04-29 | 2018 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 679,952 | 0 | 944,385 | 428,400 | 39,377 | 4,845,627 |
| 2019-04-22 | 2016 | Karah Parschauer General Counsel and Executive Vice President | 175,000 | 50,000 | 408,750 | 76,455 | 19,504 | 2,700,913 |
| 2019-04-22 | 2018 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 679,952 | 0 | 944,385 | 428,400 | 39,377 | 4,845,627 |
| 2019-04-22 | 2017 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 638,115 | 0 | 1,319,303 | 393,000 | 39,247 | 6,684,899 |
| 2019-04-22 | 2016 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 567,200 | 0 | 755,099 | 340,320 | 38,383 | 4,423,362 |
| 2019-04-22 | 2018 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 491,369 | 0 | 339,010 | 198,695 | 32,827 | 2,081,721 |
| 2019-04-22 | 2017 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 455,785 | 0 | 424,043 | 188,315 | 32,697 | 2,642,719 |
| 2019-04-22 | 2016 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 441,000 | 0 | 282,280 | 185,220 | 32,218 | 1,966,411 |
| 2019-04-22 | 2018 | Camille L. Bedrosian, M.D. | 442,308 | 210,000 | 990,000 | 189,274 | 107,727 | 4,846,292 |
| 2019-04-22 | 2018 | Wladimir Hogenhuis, M.D. | 110,923 | 200,000 | 1,159,500 | 67,021 | 215,827 | 5,257,804 |
| 2019-04-22 | 2018 | Karah Parschauer General Counsel and Executive Vice President | 386,251 | 0 | 363,225 | 175,940 | 32,819 | 2,036,330 |
| 2019-04-22 | 2017 | Karah Parschauer General Counsel and Executive Vice President | 357,310 | 0 | 246,443 | 150,070 | 19,680 | 1,434,308 |
| 2018-04-27 | 2016 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 433,000 | 50,000 | 239,938 | 181,860 | 32,403 | 2,262,065 |
| 2018-04-27 | 2017 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 447,517 | 50,000 | 468,443 | 180,389 | 36,345 | 2,834,707 |
| 2018-04-27 | 2015 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 420,000 | 0 | 373,516 | 182,700 | 28,082 | 2,382,302 |
| 2018-04-27 | 2016 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 441,000 | 0 | 282,280 | 185,220 | 32,218 | 1,966,411 |
| 2018-04-27 | 2017 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 455,785 | 0 | 424,043 | 188,315 | 32,697 | 2,642,719 |
| 2018-04-27 | 2015 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 535,000 | 0 | 967,746 | 280,875 | 38,419 | 5,400,660 |
| 2018-04-27 | 2016 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 567,200 | 0 | 755,099 | 340,320 | 38,383 | 4,423,362 |
| 2018-04-27 | 2017 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 638,115 | 0 | 1,319,303 | 393,000 | 39,247 | 6,684,899 |
| 2018-04-27 | 2015 | Thomas Kassberg Chief Business Officers and Executive Vice President | 390,000 | 0 | 373,516 | 165,750 | 30,996 | 2,338,266 |
| 2018-04-27 | 2015 | John R. Pinion II Chief Quality Officer and Executive Vice President of Translational Sciences | 171,432 | 0 | 936,525 | 79,945 | 10,681 | 7,930,191 |
| 2018-04-27 | 2016 | John R. Pinion II Chief Quality Officer and Executive Vice President of Translational Sciences | 399,185 | 0 | 211,710 | 167,658 | 34,614 | 2,035,462 |
| 2018-04-27 | 2017 | John R. Pinion II Chief Quality Officer and Executive Vice President of Translational Sciences | 412,568 | 0 | 308,603 | 170,459 | 36,491 | 1,919,329 |
| 2018-04-27 | 2016 | Thomas Kassberg Chief Business Officers and Executive Vice President | 405,600 | 0 | 282,280 | 166,296 | 35,561 | 1,915,430 |
| 2018-04-27 | 2017 | Thomas Kassberg Chief Business Officers and Executive Vice President | 418,443 | 0 | 335,243 | 168,600 | 32,697 | 2,331,661 |
| 2018-04-27 | 2015 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 164,279 | 100,000 | 1,164,500 | 74,724 | 40,603 | 7,810,279 |
| 2017-04-28 | 2014 | Karah Parschauer General Counsel and Executive Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-28 | 2015 | Karah Parschauer General Counsel and Executive Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-28 | 2016 | Karah Parschauer General Counsel and Executive Vice President | 175,000 | 50,000 | 408,750 | 76,455 | 19,504 | 2,700,913 |
| 2017-04-28 | 2014 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-28 | 2015 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 164,279 | 100,000 | 1,164,500 | 74,724 | 40,603 | 7,810,279 |
| 2017-04-28 | 2016 | Jayson Dallas, M.D. Chief Commercial Officer and Executive Vice President | 433,000 | 50,000 | 239,938 | 181,860 | 32,403 | 2,262,065 |
| 2017-04-28 | 2014 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 350,000 | 30,000 | 0 | 117,563 | 14,500 | 512,063 |
| 2017-04-28 | 2015 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 420,000 | 0 | 373,516 | 182,700 | 28,082 | 2,382,302 |
| 2017-04-28 | 2016 | Shalini Sharp, Chief Financial Officer and Executive Vice President | 441,000 | 0 | 282,280 | 185,220 | 32,218 | 1,966,411 |
| 2017-04-28 | 2015 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 535,000 | 0 | 967,746 | 280,875 | 38,419 | 5,400,660 |
| 2017-04-28 | 2016 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 567,200 | 0 | 755,099 | 340,320 | 38,383 | 4,423,362 |
| 2017-04-28 | 2014 | John R. Pinion II Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-28 | 2015 | John R. Pinion II Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research | 171,432 | 0 | 936,525 | 79,945 | 10,681 | 7,930,191 |
| 2017-04-28 | 2016 | John R. Pinion II Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research | 399,185 | 0 | 211,710 | 167,658 | 34,614 | 2,035,462 |
| 2016-04-18 | 2014 | Jayson Dallas, M.D. Chief Commercial Officer and Senior Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-18 | 2015 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 535,000 | 0 | 967,746 | 280,875 | 38,419 | 5,400,660 |
| 2016-04-18 | 2014 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 496,867 | 0 | 0 | 175,000 | 27,163 | 699,030 |
| 2016-04-18 | 2015 | Shalini Sharp, Chief Financial Officer and Senior Vice President | 420,000 | 0 | 373,516 | 182,700 | 28,082 | 2,382,302 |
| 2016-04-18 | 2014 | Shalini Sharp, Chief Financial Officer and Senior Vice President | 350,000 | 30,000 | 0 | 117,563 | 14,500 | 512,063 |
| 2016-04-18 | 2013 | Shalini Sharp, Chief Financial Officer and Senior Vice President | 278,440 | 30,000 | 0 | 110,206 | 24,193 | 625,233 |
| 2016-04-18 | 2015 | Dennis Huang Chief Technical Operations Officer and Senior Vice President | 215,135 | 0 | 469,725 | 95,805 | 20,390 | 4,242,541 |
| 2016-04-18 | 2014 | Dennis Huang Chief Technical Operations Officer and Senior Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-18 | 2013 | Dennis Huang Chief Technical Operations Officer and Senior Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-18 | 2015 | John R. Pinion II Operations Officer Sciences and Research | 171,432 | 0 | 936,525 | 79,945 | 10,681 | 7,930,191 |
| 2016-04-18 | 2014 | John R. Pinion II Operations Officer Sciences and Research | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-18 | 2013 | John R. Pinion II Operations Officer Sciences and Research | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-18 | 2015 | Jayson Dallas, M.D. Chief Commercial Officer and Senior Vice President | 164,279 | 100,000 | 1,164,500 | 74,724 | 40,603 | 7,810,279 |
| 2016-04-18 | 2013 | Jayson Dallas, M.D. Chief Commercial Officer and Senior Vice President | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-28 | 2013 | Sunil Agarwal, M.D. Senior Vice President and Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-04-28 | 2014 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 496,867 | 0 | 0 | 175,000 | 27,163 | 699,030 |
| 2015-04-28 | 2013 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 306,034 | 0 | 0 | 140,910 | 19,721 | 685,538 |
| 2015-04-28 | 2014 | Thomas Kassberg Senior Vice President | 362,857 | 0 | 0 | 112,219 | 16,863 | 491,939 |
| 2015-04-28 | 2013 | Thomas Kassberg Senior Vice President | 289,419 | 0 | 0 | 114,345 | 20,352 | 606,510 |
| 2015-04-28 | 2014 | Sunil Agarwal, M.D. Senior Vice President and Chief Medical Officer | 150,180 | 100,000 | 1,397,000 | 164,588 | 7,530 | 7,210,630 |
| 2014-05-23 | 2012 | Shalini Sharp Chief Financial Officer and Senior Vice President | 148,669 | 0 | 0 | 51,560 | 13,228 | 303,499 |
| 2014-05-23 | 2012 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 300,172 | 0 | 0 | 92,125 | 9,056 | 401,353 |
| 2014-05-23 | 2013 | Thomas Kassberg Chief Business Officer | 289,419 | 0 | 0 | 114,345 | 20,352 | 606,510 |
| 2014-05-23 | 2012 | Thomas Kassberg Chief Business Officer | 272,041 | 0 | 0 | 81,813 | 15,640 | 369,494 |
| 2014-05-23 | 2013 | Shalini Sharp Chief Financial Officer and Senior Vice President | 278,440 | 30,000 | 0 | 110,206 | 24,193 | 625,233 |
| 2014-05-23 | 2013 | Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | 306,034 | 0 | 0 | 140,910 | 19,721 | 685,538 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
